Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants

J Infect Dis. 2023 May 29;227(11):1333-1334. doi: 10.1093/infdis/jiac488.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Immunization
  • Infant
  • Respiratory Syncytial Virus, Human* / immunology
  • Seasons

Substances

  • nirsevimab
  • Antibodies, Monoclonal, Humanized